ACC CardiaCast 2023 ACC Expert Consensus Decision Pathway on Management of Patients with HFpEF
6 snips
Oct 16, 2025 Clyde W. Yancy, MD, MSc, MACC, a renowned cardiologist and Vice Dean for Health Equity, dives into the latest guidelines for managing HFpEF. He emphasizes the importance of prevention strategies like lifestyle changes and blood pressure control. The discussion highlights innovative treatments, including SGLT2 inhibitors, and the role of natriuretic peptides in patient evaluation. Yancy also addresses gaps in implementation and the potential of combination therapies to lower cardiovascular mortality, making for a compelling and informative conversation.
AI Snips
Chapters
Transcript
Episode notes
Aggressively Manage Cardiometabolic Risks
- Control blood pressure, manage weight, and treat diabetes aggressively to prevent HFpEF.
- Screen for sleep apnea and atrial arrhythmias in high-risk patients to reduce HFpEF risk.
HFpEF Demographics And Biomarker Nuances
- HFpEF disproportionately affects women and links tightly with obesity and hypertension.
- Natriuretic peptide levels are lower in heavier patients, so interpret modest rises cautiously.
Initiate SGLT2 Inhibitors Early
- Start SGLT2 inhibitors early for HFpEF because benefits emerge within days to weeks.
- Use SGLT2 inhibitors regardless of diabetes status to reduce HF hospitalizations and CV events.